NVOS Novo Integrated Sciences Inc

Accounts Receivables, Net

Note 4 – Accounts Receivables, Net

Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Accounts Receivable, Net

	November 30,			August 31,
	2023			2023
Trade receivables	$	3,412,783		$	2,223,243
Amounts earned but not billed		78,507			108,000
Accounts receivables gross		3,491,290			2,331,243
Allowance for doubtful accounts		(855,116	)		(864,215	)
Accounts receivable, net	$	2,636,174		$	1,467,028

Inventory

3 Months Ended

Nov. 30, 2023

Inventory Disclosure [Abstract]

Inventory

Note 5 – Inventory

Inventory at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Inventory

	November 30,		August 31,
	2023		2023
Raw materials	$	516,811	$	388,391
Work in process		108,244		81,696
Finished Goods		645,780		636,896
Inventory Gross		1,270,835		1,106,983
Allowance for slow moving and obsolete inventory		-		-
Inventory, net	$	1,270,835	$	1,106,983

Other Receivables

3 Months Ended

Nov. 30, 2023

Property, Plant and Equipment [Abstract]

Other Receivables

Note 6 – Other Receivables

Other receivables at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Other Receivables

	November 30, 2023			August 31, 2023
Advance to corporation; accrues interest at 12% per annum; unsecured; due January 31, 2024, as amended.	$	73,630		$	73,900
Advance to corporation; accrues interest at 12% per annum; secured by property and other assets of debtor; due February 1, 2024, as amended.		532,433			534,386
Advance to corporation; accrues interest at 10% per annum; secured by assets of debtor; due February 1, 2024, as amended.		441,679			443,298
Total other receivables		1,047,742			1,051,584
Current portion		(1,047,742	)		(1,051,584	)
Long-term portion	$	-		$	-

Property and Equipment

3 Months Ended

Nov. 30, 2023

Property and Equipment

Note 7 – Property and Equipment

Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Property and Equipment

	November 30,			August 31,
	2023			2023
Land	$	441,780		$	443,400
Building		3,313,350			3,325,500
Leasehold improvements		838,297			841,371
Clinical equipment		1,909,678			1,916,681
Computer equipment		33,381			33,504
Office equipment		44,400			44,502
Furniture and fixtures		38,149			38,289
Property and Equipment gross		6,619,035			6,643,247
Accumulated depreciation		(1,312,422	)		(1,253,209	)
Total	$	5,306,613		$	5,390,038

Depreciation expense for the three months ended November 30, 2023 and 2022 was $72,604 and $60,043, respectively.

Certain property and equipment have been used to secure notes payable (See Note 10).

Intangible Assets

3 Months Ended

Nov. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 8 – Intangible Assets

Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Intangible Assets

	November 30,			August 31,
	2023			2023
Land use rights	$	11,573,321		$	11,573,321
Intellectual property		7,487,410			7,497,746
Customer relationships		2,287,746			2,291,058
Brand names		1,921,375			1,928,421
Finite lived intangible assets, gross		23,269,852			23,290,546
Accumulated amortization		(7,565,634	)		(7,072,007	)
Total	$	15,704,218		$	16,218,539

Amortization expense for the three months ended November 30, 2023 and 2022 was $499,800 and $526,123, respectively.

Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows:

Twelve Months Ending November 30,
2024	$	2,003,586
2025		1,820,324
2026		1,454,624
2027		1,208,004
2028		639,025
Thereafter		8,578,655
Total	$	15,704,218

Accrued Expenses

3 Months Ended

Nov. 30, 2023

Payables and Accruals [Abstract]

Accrued Expenses

Note 9 – Accrued Expenses

Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Accrued Expenses

	November 30,		August 31,
	2023		2023
Accrued liabilities	$	1,049,543	$	961,897
Accrued payroll		215,936		236,218
Unearned revenue		35,070		35,434
Accrued expense	$	1,300,549	$	1,233,549

Government Loans and Notes Payable

3 Months Ended

Nov. 30, 2023

Government Loans And Notes Payable

Government Loans and Notes Payable

Note 10 – Government Loans and Notes Payable

Notes payable at November 30, 2023 and August 31, 2023 consisted of the following:

	November 30,			August 31,
	2023			2023
Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A).		88,356			88,680
Note payable to the Small Business Administration. The note bears interest at 3.75% per annum, requires monthly payments of $190 after 12 months from funding and is due 30 years from the date of issuance, and is secured by certain equipment of PRO-DIP.		40,320			40,320
Note payable dated December 3, 2018; accrues interest at 4.53% per annum; unsecured; annual payments of approximately $4,000; due December 2, 2028		28,589			28,693
Note payable received May 25, 2023, accruing interest at 18% per 3-months term, unsecured, with principal and interest due 3-month from loan issuance. The note was repaid on October 26, 2023.		-			73,900
Note payable received May 10, 2023, accruing interest at 15% per 4-months term, with a first priority security interest in all of Acenzia’s production equipment, with principal and interest due 4-month from loan issuance. The note was repaid on October 23, 2023.		-			110,850
Total government loans and notes payable		157,265			342,443
Less current portion		(93,488	)		(277,405	)
Long-term portion	$	63,777		$	65,038

(A)

Future scheduled maturities of outstanding government loans and notes payable are as follows:

Twelve Months Ending November 30,
2024	$	93,488
2025		6,470
2026		6,469
2027		6,469
2028		6,469
Thereafter		37,900
Total	$	157,265

Convertible Notes Payable

3 Months Ended

Nov. 30, 2023

Convertible Notes Payable

Convertible Notes Payable

Note 11 – Convertible Notes Payable

Novo Integrated

	●	Expected life of 4.0 years;
	●	Volatility of 275%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 1.23%

	●	Expected life of 0.58 years;
	●	Volatility of 148.20%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 4.55%

The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible notes.

During the year ended August 31, 2023, the Company amortized $4,241,429 of the debt discount and as of November 30, 2023 and August 31, 2023, the unamortized debt discount was $nil.

Terragenx

●	Expected life of 3.0 years;
●	Volatility of 300%;
●	Dividend yield of 0%; and
●	Risk free interest rate of 0.85%

Novo Integrated – Mast Hill Fund, L.P.

	●	Expected life of 5.0 years;
	●	Volatility of 252%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 4.09%

Novo Integrated – FirstFire Global Opportunities Fund, LLC

	●	Expected life of 5.0 years;
	●	Volatility of 251%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 3.73%

Novo Integrated – Mast Hill Fund, L.P. $445,000 Note, SPA, and Warrant

	●	Expected life of 5.0 years;
	●	Volatility of 251%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 3.96%

September 2023 Mast Hill SPA

	●	Expected life of 1 year;
	●	Volatility of 182.17%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 5.42%

The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note.

	●	Expected life of 0.79 years;
	●	Volatility of 193.48%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 5.16%

The September 2023 Mast Hill Note contained a discount on note of $3,500,000. The total discount will be amortized over the life of the September 2023 Mast Hill Note.

During the three months ended November 30, 2023, the Company amortized $755,464 of the debt discount and as November 30, 2023, the unamortized debt discount was $2,744,536.

September 2023 FirstFire SPA & Note

The Company determined that the conversion features of these notes represented embedded derivatives since the notes are convertible into a variable number of shares upon conversion. On September 18, 2023, the Company recorded a derivative liability of $200,136. The fair value of the derivative liability was calculated using the Black-Scholes pricing model with the following assumptions:

	●	Expected life of 1 year;
	●	Volatility of 180.36%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 5.44%

The derivative was recorded as a discount on the convertible notes, but only for an amount not in excess of and thus capped by the otherwise undiscounted amount of the convertible note.

	●	Expected life of 0.80 years;
	●	Volatility of 193.48%;
	●	Dividend yield of 0%; and
	●	Risk free interest rate of 5.16%

The September 2023 FirstFire Note contained a discount on note of $235,414. The total discount will be amortized over the life of the September 2023 FirstFire Note.

During the three months ended November 30, 2023, the Company amortized $46,954 of the debt discount and as November 30, 2023, the unamortized debt discount was $188,460.

Debentures, Related Parties

3 Months Ended

Nov. 30, 2023

Debt Disclosure [Abstract]

Debentures, Related Parties

Note 12 – Debentures, Related Parties

On July 21, 2020, the Company made a partial repayment of a debenture due to a related party of $267,768.

At November 30, 2023 and August 31, 2023, the amount of debentures outstanding was $913,474 and $916,824, respectively.

Leases

3 Months Ended

Nov. 30, 2023

Leases

Leases

Note 13 – Leases

Operating leases

The Company leases its corporate office space and certain facilities under long-term operating leases expiring through fiscal year 2031.

The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023:

		November 30,		August 31,
		2023		2023
	Classification on Balance Sheet
Assets
Operating lease assets	Operating lease right of use assets	$	1,870,204	$	1,983,898
Total lease assets		$	1,870,204	$	1,983,898

Liabilities
Current liabilities
Operating lease liability	Current operating lease liability	$	413,506	$	415,392
Noncurrent liabilities
Operating lease liability	Long-term operating lease liability		1,585,667		1,693,577
Total lease liability		$	1,999,173	$	2,108,969

Future minimum operating lease payments are as follows:

Schedule of Operating Lease Payments

Twelve Months Ending November 30,
2024	$	568,536
2025		494,272
2026		512,495
2027		417,394
2028		223,188
Thereafter		254,641
Total payments		2,470,526
Amount representing interest		(471,353	)
Lease obligation, net		1,999,173
Less lease obligation, current portion		413,506
Lease obligation, long-term portion	$	1,585,667

During the three months ended November 30, 2023, the Company did not enter into any new lease obligation.

Finance Leases

Schedule of Finance Leases

	November 30,		August 31,
	2023		2023
Cost	$	209,457	$	209,457
Accumulated amortization		(209,457)		(209,457)
Net book value	$	-	$	-

Future minimum finance lease payments are as follows:

Twelve Months Ending November 30,
2024	$	8,973
Total payments		8,973
Amount representing interest		(66	)
Lease obligation, net		8,907
Less lease obligation, current portion		(8,907	)
Lease obligation, long-term portion	$	-

Stockholders’ Equity

3 Months Ended

Nov. 30, 2023

Equity [Abstract]

Stockholders’ Equity

Note 14 – Stockholders’ Equity

Reverse Stock Split

Convertible Preferred Stock

Common Stock

During the three-month period ended November, 2023, the Company issued common stock as follows:

	●	80,200 shares of common stock were issued to various warrant holders upon exercise of their 3-year warrants. The warrants were issued on October 18, 2022, under the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the Securities and Exchange Commission (the “SEC”) on October 13, 2022. The net proceeds were $80,200. The shares were issued on various dates during the 3-month period.

	●	160,200 shares of common stock were issued to various warrant holders upon exercise of their 5-year warrants. The warrants were issued on October 18, 2022, under the prospectus contained in the Registration Statement on Form S-1 (File No. 333-267401) declared effective by the SEC on October 13, 2022. The net proceeds were $160,200. The shares were issued on various dates during the 3-month period.

	●	75,000 restricted shares of common stock as consideration pursuant to a consulting agreement. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on September 5, 2023.

	●	53,567 shares were issued to Mast Hill upon the cashless exercise of all warrants. The warrants were issued on February 23, 2023 under the terms and conditions of the warrant agreement between the Company and Mast Hill in connection with the $573,000 promissory note issued, by the Company to Mast Hill, on February 23, 2023. The shares were issued on September 18, 2023.

	●	75,000 restricted shares of common stock were issued as consideration pursuant to a consulting agreement. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on September 18, 2023.

	●	519,845 restricted shares of common stock were issued to FirstFire upon conversion of outstanding debt pursuant to the terms of the securities purchase agreement between FirstFire and the Company. The debt amount converted consisted of principal amount of $573,000 and interest of $4,521, for a total amount of $577,521. The shares were issued on September 21, 2023.

	●	75,000 restricted shares of common stock were issued as consideration pursuant to a consulting agreement. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on October 3, 2023.

	●	73,767 restricted shares of common stock were issued in exchange for certain non-voting special shares of NHL, previously issued in connection with NHL’s Share Exchange Agreement with the Terragenx shareholders, the Company’s Asset Purchase Agreement with Mr. Terrence Mullins, and an employment agreement with Mr. Terrence Mullins, each of which closed on November 17, 2021. The fair value was determined based on the market price of the Company’s common stock on the date of closing. The shares were issued on October 9, 2023.

	●	53,532 shares were issued to FirstFire upon the cashless exercise of all warrants. The warrants were issued on March 21, 2023 under the terms and conditions of the warrant agreement between the Company and Mast Hill in connection with the $573,000 promissory note issued, by the Company to FirstFire, on March 21, 2023. The shares were issued on October 12, 2023.

	●	75,000 restricted shares of common stock were issued as consideration pursuant to a consulting agreement. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on October 18, 2023.

	●	138,703 shares were issued to Mast Hill upon the cashless exercise of all warrants. The warrants were granted on June 20, 2023 under the terms and conditions of the warrant agreement between the Company and Mast Hill in connection with the $445,000 promissory note issued, by the Company to Mast Hill, on June 20, 2023. The shares were issued on October 23, 2023.

	●	75,000 restricted shares of common stock were issued as consideration pursuant to a consulting agreement. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on November 8, 2023.

	●	30,675 restricted shares of common stock were issued pursuant to the terms and conditions of an executive agreement, dated November 15, 2022, between NHL and an officer of NHL. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on November 21, 2023.

	●	18,405 restricted shares of common stock were issued pursuant to the terms and conditions of an executive agreement, dated November 15, 2022, between NHL and an officer of NHL. The fair value was determined based on the market price of the Company’s common stock on the date of issuance. The shares were issued on November 21, 2023.

	●	27,973 shares of common stock issued in lieu of fractional shares resulting from the Company’s 1-for-10 reverse stock split of its common stock, effective November 7, 2023. As a result of the reverse stock split, every 10 shares of issued and outstanding common stock were exchanged for one share of common stock, with any fractional shares being rounded up to the next higher whole share.

Common Stock to be Issued

Stock Options

The following is a summary of stock options activity:

Schedule of Stock Option Activity

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Options		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, August 31, 2023		371,423		11.44		3.98	$	16,000
Granted		-
Forfeited		-
Exercised		-
Outstanding, November 30, 2023		371,423		11.44		3.73	$	-
Exercisable, November 30, 2023		371,423	$	11.44		3.73	$	-

The exercise price for stock options outstanding at November 30, 2023:

Outstanding				Exercisable
Number of		Exercise		Number of		Exercise
Options		Price		Options		Price
	22,715	$	13.30		22,715	$	13.30
	54,200		16.00		54,200		16.00
	4,800		18.70		4,800		18.70
	77,500		30.00		77,500		30.00
	7,260		38.00		7,260		38.00
	1,000		50.00		1,000		50.00
	3,948		19.00		3,948		19.00
	200,000		1.32		200,000		1.32
	371,423				371,423

No options were granted during the three months ended November 30, 2023 and 2022.

Warrants

The following is a summary of warrant activity:

Schedule of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Warrants			Exercise		Contractual		Intrinsic
	Outstanding			Price		Life		Value
Outstanding, August 31, 2023		806,254		$	12.05		3.71	$	106,960
Granted		-
Forfeited		-
Exercised		(518,061	)
Outstanding, November 30, 2023		288,193		$	30.46		3.46	$	5,400
Exercisable, November 30, 2023		288,193		$	30.46		3.46	$	5,400

The exercise price for warrants outstanding at November 30, 2023:

Schedule of Warrants Outstanding

Commitments and Contingencies

3 Months Ended

Nov. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 15 – Commitments and Contingencies

Litigation

Segment Reporting

3 Months Ended

Nov. 30, 2023

Segment Reporting [Abstract]

Segment Reporting

Note 16 – Segment Reporting

ASC Topic 280, Segment Reporting, requires use of the “management approach” model for segment reporting. The management approach model is based on the way a company’s management organizes segments within the Company for making operating decisions and assessing performance. The Company has two reportable segments: healthcare services and product sales.

The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022:


	Three Months Ended November 30,
	2023			2022

Sales
Healthcare services	$	2,044,510		$	2,021,213
Product manufacturing and development		1,768,458			790,478
Corporate		78,250			607,589
Sales	$	3,891,218		$	3,419,280

Gross profit
Healthcare services	$	676,416		$	784,031
Product manufacturing and development		1,189,352			347,914
Corporate		78,250			607,588
Gross profit	$	1,944,018		$	1,739,533

(Loss) income from operations
Healthcare services	$	(80,327	)	$	(151,691	)
Product manufacturing and development		108,702			(554,842	)
Corporate		(3,346,012	)		(1,535,427	)
Income (loss) from operations	$	(3,317,637	)	$	(2,241,960	)

Depreciation and amortization
Healthcare services	$	30,035		$	28,968
Product manufacturing and development		262,927			309,042
Corporate		279,442			248,156
Depreciation and amortization	$	572,404		$	586,166

Capital expenditures
Healthcare services	$	-		$	-
Product manufacturing and development		-			-
Corporate		-			-
Capital expenditures	$	-		$	-

Interest expenses
Healthcare services	$	20,532		$	36,303
Product manufacturing and development		462			2,464
Corporate		122,380			128,476
Interest expenses	$	143,374		$	167,243

Net (loss) income
Healthcare services	$	(98,640	)	$	(185,713	)
Product manufacturing and development		48,883			(578,576	)
Corporate		(4,610,966	)		(3,172,447	)
Net loss	$	(4,660,723	)	$	(3,936,736	)

	As of November 30, 2023		As of August 31, 2023

Total assets
Healthcare services	$	5,002,855	$	5,158,851
Product Sales		18,748,475		17,993,652
Corporate		13,493,054		12,410,544
	$	37,244,384	$	35,563,047

Accounts receivable
Healthcare services	$	672,841	$	697,440
Product Sales		1,868,387		765,388
Corporate		94,946		4,200
	$	2,636,174	$	1,467,028

Intangible assets
Healthcare services	$	111,172	$	120,163
Product Sales		3,592,425		3,818,313
Corporate		12,000,621		12,280,063
	$	15,704,218	$	16,218,539

Goodwill
Healthcare services	$	518,918	$	520,821
Product Sales		7,035,861		7,061,662
Corporate		-		-
	$	7,554,779	$	7,582,483

Subsequent Events

3 Months Ended

Nov. 30, 2023

Subsequent Events [Abstract]

Subsequent Events

Note 17 – Subsequent Events

Purchase and Sale Agreement – Ophir Collection

Within two business days following the Company’s execution of the Ophir Agreement, the Company was required to, and did, deposit $25,000 (the “Deposit”) with the Successor Receiver.

Pursuant to the terms of the Ophir Agreement, the Company agreed to pay $60,000,000 to the Successor Receiver to purchase the Ophir Collection as follows:

	(i)	The Company has the right, at all times after November 21, 2023, to conduct a full and unfettered inspection of the Ophir Collection. While the Company has the right to inspect the Ophir Collection prior to closing, the Company’s inspection will not be a contingency to closing and the inability of the Company to inspect (or the Company’s decision not to inspect) the Ophir Collection prior to closing will not delay or prevent closing.

	(ii)	After the Successor Receiver obtains Court approval of the Ophir Agreement, the Company will cause $59,975,000 (representing the $60,000,000 purchase price, less the Deposit) to be paid to the Successor Receiver, on or before December 19, 2023. Although such amount has not yet been delivered to the Successor Receiver, the parties continue to work toward closing.

	(iii)	Within one business day thereafter, the Successor Receiver will assign, transfer, convey and deliver free and clear title and interest in and to, and possession of, the Ophir Collection to the Company.

Mast Hill Conversion of Debt on $445,000 Promissory Note

Interest Payment on September 2023 Mast Hill Note

On December 12, 2023, the Company made an interest-only payment of $104,712 to Mast Hill pursuant to the terms of the September 2023 Mast Hill Note.

Interest Payment on September 2023 FirstFire Note

On December 18, 2023, the Company made an interest-only payment of $8,333 to FirstFire pursuant to the terms of the September 2023 FirstFire Note.

Officer Option Grant

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Nov. 30, 2023

Accounting Policies [Abstract]

Use of Estimates

Principles of Consolidation

All intercompany transactions have been eliminated.

Noncontrolling Interest

The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss.

Property and Equipment

Building		30 years
Leasehold improvements		5 years
Clinical equipment		5 years
Computer equipment		3 years
Office equipment		5 years
Furniture and fixtures		5 years

Leases

Long-Lived Assets

Intangible Assets

The Company’s intangible assets are being amortized over their estimated useful lives as follows:

Land use rights		50 years (the lease period)
Intellectual property		7 years
Customer relationships		5 years
Brand names		7 years

Right-of-use Assets

Goodwill

Summary of changes in goodwill by acquired businesses is as follows:

Schedule of Changes in Goodwill

	APKA			EFL			Rockland			Acenzia			1285 Canada			Total
Balance, August 31, 2022	$	190,678		$	125,088		$	221,188		$	7,288,307		$	583		$	7,825,844
Foreign currency translation adjustment		(5,928	)		(3,892	)		(6,878	)		(226,645	)		(18	)		(243,361	)
Balance, August 31, 2023	$	184,750		$	121,196		$	214,310		$	7,061,662		$	565		$	7,582,483
Beginning balance	$	184,750		$	121,196		$	214,310		$	7,061,662		$	565		$	7,582,483
Foreign currency translation adjustment		(675	)		(443	)		(783	)		(25,801	)		(2	)		(27,704	)
Balance, November 30, 2023	$	184,075		$	120,753		$	213,527		$	7,035,861		$	563		$	7,554,779
Ending balance	$	184,075		$	120,753		$	213,527		$	7,035,861		$	563		$	7,554,779

Fair Value of Financial Instruments

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the fair value measurement.

Derivative Financial Instruments

Revenue Recognition

	●	executed contracts with the Company’s customers that it believes are legally enforceable;
	●	identification of performance obligations in the respective contract;
	●	determination of the transaction price for each performance obligation in the respective contract;
	●	allocation the transaction price to each performance obligation; and
	●	recognition of revenue only when the Company satisfies each performance obligation.

These five elements, as applied to the Company’s revenue category, are summarized below:

	●	Healthcare and healthcare related services – gross service revenue is recorded in the accounting records at the time the services are provided (point-in-time) on an accrual basis at the provider’s established rates. The Company reserves a provision for contractual adjustment and discounts that are deducted from gross service revenue. The Company reports revenues net of any sales, use and value added taxes.
	●	Product sales – revenue is recorded at the point of time of delivery.

Income Taxes

Stock-Based Compensation

Basic and Diluted Earnings Per Share

Due to the net loss incurred, potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss per share for all periods presented.

Foreign Currency Transactions and Comprehensive Income

Condensed Consolidated Statements of Cash Flows

Segment Reporting

Reclassifications

Certain prior period amounts were reclassified to conform to the manner of presentation in the current period. These reclassifications had no effect on the net loss or shareholders’ equity.

Recent Accounting Pronouncements

Organization and Basis of Presentation (Tables)

3 Months Ended

Nov. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Foreign Currency Translation, Exchange Rate Used

	November 30, 2023		November 30, 2022		August 31, 2023

Period end: CAD to USD exchange rate	$	0.7363	$	0.7403	$	0.7390
Average period: CAD to USD exchange rate	$	0.7324	$	0.7414	$	0.7426

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Nov. 30, 2023

Accounting Policies [Abstract]

Schedule of Estimated Useful lives of Assets

Building		30 years
Leasehold improvements		5 years
Clinical equipment		5 years
Computer equipment		3 years
Office equipment		5 years
Furniture and fixtures		5 years

Schedule of Intangible Assets Amortized Estimated Useful Lives

The Company’s intangible assets are being amortized over their estimated useful lives as follows:

Land use rights		50 years (the lease period)
Intellectual property		7 years
Customer relationships		5 years
Brand names		7 years

Schedule of Changes in Goodwill

Summary of changes in goodwill by acquired businesses is as follows:

Schedule of Changes in Goodwill

	APKA			EFL			Rockland			Acenzia			1285 Canada			Total
Balance, August 31, 2022	$	190,678		$	125,088		$	221,188		$	7,288,307		$	583		$	7,825,844
Foreign currency translation adjustment		(5,928	)		(3,892	)		(6,878	)		(226,645	)		(18	)		(243,361	)
Balance, August 31, 2023	$	184,750		$	121,196		$	214,310		$	7,061,662		$	565		$	7,582,483
Beginning balance	$	184,750		$	121,196		$	214,310		$	7,061,662		$	565		$	7,582,483
Foreign currency translation adjustment		(675	)		(443	)		(783	)		(25,801	)		(2	)		(27,704	)
Balance, November 30, 2023	$	184,075		$	120,753		$	213,527		$	7,035,861		$	563		$	7,554,779
Ending balance	$	184,075		$	120,753		$	213,527		$	7,035,861		$	563		$	7,554,779

Accounts Receivables, Net (Tables)

3 Months Ended

Nov. 30, 2023

Schedule of Accounts Receivable, Net

Accounts receivables, net at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Accounts Receivable, Net

	November 30,			August 31,
	2023			2023
Trade receivables	$	3,412,783		$	2,223,243
Amounts earned but not billed		78,507			108,000
Accounts receivables gross		3,491,290			2,331,243
Allowance for doubtful accounts		(855,116	)		(864,215	)
Accounts receivable, net	$	2,636,174		$	1,467,028

Inventory (Tables)

3 Months Ended

Nov. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventory

Inventory at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Inventory

	November 30,		August 31,
	2023		2023
Raw materials	$	516,811	$	388,391
Work in process		108,244		81,696
Finished Goods		645,780		636,896
Inventory Gross		1,270,835		1,106,983
Allowance for slow moving and obsolete inventory		-		-
Inventory, net	$	1,270,835	$	1,106,983

Other Receivables (Tables)

3 Months Ended

Nov. 30, 2023

Schedule of Other Receivables

Other receivables at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Other Receivables

	November 30, 2023			August 31, 2023
Advance to corporation; accrues interest at 12% per annum; unsecured; due January 31, 2024, as amended.	$	73,630		$	73,900
Advance to corporation; accrues interest at 12% per annum; secured by property and other assets of debtor; due February 1, 2024, as amended.		532,433			534,386
Advance to corporation; accrues interest at 10% per annum; secured by assets of debtor; due February 1, 2024, as amended.		441,679			443,298
Total other receivables		1,047,742			1,051,584
Current portion		(1,047,742	)		(1,051,584	)
Long-term portion	$	-		$	-

Property and Equipment (Tables)

3 Months Ended

Nov. 30, 2023

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

Property and equipment at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Property and Equipment

	November 30,			August 31,
	2023			2023
Land	$	441,780		$	443,400
Building		3,313,350			3,325,500
Leasehold improvements		838,297			841,371
Clinical equipment		1,909,678			1,916,681
Computer equipment		33,381			33,504
Office equipment		44,400			44,502
Furniture and fixtures		38,149			38,289
Property and Equipment gross		6,619,035			6,643,247
Accumulated depreciation		(1,312,422	)		(1,253,209	)
Total	$	5,306,613		$	5,390,038

Intangible Assets (Tables)

3 Months Ended

Nov. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Intangible Assets

Intangible assets at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Intangible Assets

	November 30,			August 31,
	2023			2023
Land use rights	$	11,573,321		$	11,573,321
Intellectual property		7,487,410			7,497,746
Customer relationships		2,287,746			2,291,058
Brand names		1,921,375			1,928,421
Finite lived intangible assets, gross		23,269,852			23,290,546
Accumulated amortization		(7,565,634	)		(7,072,007	)
Total	$	15,704,218		$	16,218,539

Schedule of Expected Amortization Expense of intangible Assets

Expected amortization expense of intangible assets over the next 5 years and thereafter is as follows:

Twelve Months Ending November 30,
2024	$	2,003,586
2025		1,820,324
2026		1,454,624
2027		1,208,004
2028		639,025
Thereafter		8,578,655
Total	$	15,704,218

Accrued Expenses (Tables)

3 Months Ended

Nov. 30, 2023

Payables and Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses at November 30, 2023 and August 31, 2023 consisted of the following:

Schedule of Accrued Expenses

	November 30,		August 31,
	2023		2023
Accrued liabilities	$	1,049,543	$	961,897
Accrued payroll		215,936		236,218
Unearned revenue		35,070		35,434
Accrued expense	$	1,300,549	$	1,233,549

Government Loans and Notes Payable (Tables)

3 Months Ended

Nov. 30, 2023

Government Loans And Notes Payable

Schedule of Governmental Loans and Note Payable

Notes payable at November 30, 2023 and August 31, 2023 consisted of the following:

	November 30,			August 31,
	2023			2023
Government loans issued under the Government of Canada’s Canada Emergency Business Account (“CEBA”) program (A).		88,356			88,680
Note payable to the Small Business Administration. The note bears interest at 3.75% per annum, requires monthly payments of $190 after 12 months from funding and is due 30 years from the date of issuance, and is secured by certain equipment of PRO-DIP.		40,320			40,320
Note payable dated December 3, 2018; accrues interest at 4.53% per annum; unsecured; annual payments of approximately $4,000; due December 2, 2028		28,589			28,693
Note payable received May 25, 2023, accruing interest at 18% per 3-months term, unsecured, with principal and interest due 3-month from loan issuance. The note was repaid on October 26, 2023.		-			73,900
Note payable received May 10, 2023, accruing interest at 15% per 4-months term, with a first priority security interest in all of Acenzia’s production equipment, with principal and interest due 4-month from loan issuance. The note was repaid on October 23, 2023.		-			110,850
Total government loans and notes payable		157,265			342,443
Less current portion		(93,488	)		(277,405	)
Long-term portion	$	63,777		$	65,038

(A)

Schedule of Future Maturities Outstanding of government Loans and Notes Payable

Future scheduled maturities of outstanding government loans and notes payable are as follows:

Twelve Months Ending November 30,
2024	$	93,488
2025		6,470
2026		6,469
2027		6,469
2028		6,469
Thereafter		37,900
Total	$	157,265

Leases (Tables)

3 Months Ended

Nov. 30, 2023

Leases

Schedule of Lease Related Assets and Liabilities

The table below presents the lease related assets and liabilities recorded on the Company’s condensed consolidated balance sheets as of November 30, 2023 and August 31, 2023:

		November 30,		August 31,
		2023		2023
	Classification on Balance Sheet
Assets
Operating lease assets	Operating lease right of use assets	$	1,870,204	$	1,983,898
Total lease assets		$	1,870,204	$	1,983,898

Liabilities
Current liabilities
Operating lease liability	Current operating lease liability	$	413,506	$	415,392
Noncurrent liabilities
Operating lease liability	Long-term operating lease liability		1,585,667		1,693,577
Total lease liability		$	1,999,173	$	2,108,969

Schedule of Operating Lease Payments

Future minimum operating lease payments are as follows:

Schedule of Operating Lease Payments

Twelve Months Ending November 30,
2024	$	568,536
2025		494,272
2026		512,495
2027		417,394
2028		223,188
Thereafter		254,641
Total payments		2,470,526
Amount representing interest		(471,353	)
Lease obligation, net		1,999,173
Less lease obligation, current portion		413,506
Lease obligation, long-term portion	$	1,585,667

Schedule of Finance Leases

	November 30,		August 31,
	2023		2023
Cost	$	209,457	$	209,457
Accumulated amortization		(209,457)		(209,457)
Net book value	$	-	$	-

Schedule of Future Minimum Lease Payments

Future minimum finance lease payments are as follows:

Twelve Months Ending November 30,
2024	$	8,973
Total payments		8,973
Amount representing interest		(66	)
Lease obligation, net		8,907
Less lease obligation, current portion		(8,907	)
Lease obligation, long-term portion	$	-

Stockholders’ Equity (Tables)

3 Months Ended

Nov. 30, 2023

Equity [Abstract]

Schedule of Stock Option Activity

The following is a summary of stock options activity:

Schedule of Stock Option Activity

					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Options		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, August 31, 2023		371,423		11.44		3.98	$	16,000
Granted		-
Forfeited		-
Exercised		-
Outstanding, November 30, 2023		371,423		11.44		3.73	$	-
Exercisable, November 30, 2023		371,423	$	11.44		3.73	$	-

Schedule of Options Outstanding and Exercisable

The exercise price for stock options outstanding at November 30, 2023:

Outstanding				Exercisable
Number of		Exercise		Number of		Exercise
Options		Price		Options		Price
	22,715	$	13.30		22,715	$	13.30
	54,200		16.00		54,200		16.00
	4,800		18.70		4,800		18.70
	77,500		30.00		77,500		30.00
	7,260		38.00		7,260		38.00
	1,000		50.00		1,000		50.00
	3,948		19.00		3,948		19.00
	200,000		1.32		200,000		1.32
	371,423				371,423

Schedule of Warrant Activity

The following is a summary of warrant activity:

Schedule of Warrant Activity

						Weighted
				Weighted		Average
				Average		Remaining		Aggregate
	Warrants			Exercise		Contractual		Intrinsic
	Outstanding			Price		Life		Value
Outstanding, August 31, 2023		806,254		$	12.05		3.71	$	106,960
Granted		-
Forfeited		-
Exercised		(518,061	)
Outstanding, November 30, 2023		288,193		$	30.46		3.46	$	5,400
Exercisable, November 30, 2023		288,193		$	30.46		3.46	$	5,400

Schedule of Warrants Outstanding

The exercise price for warrants outstanding at November 30, 2023:

Schedule of Warrants Outstanding

Segment Reporting (Tables)

3 Months Ended

Nov. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

The following tables summarize the Company’s segment information for the three months ended November 30, 2023 and 2022:


	Three Months Ended November 30,
	2023			2022

Sales
Healthcare services	$	2,044,510		$	2,021,213
Product manufacturing and development		1,768,458			790,478
Corporate		78,250			607,589
Sales	$	3,891,218		$	3,419,280

Gross profit
Healthcare services	$	676,416		$	784,031
Product manufacturing and development		1,189,352			347,914
Corporate		78,250			607,588
Gross profit	$	1,944,018		$	1,739,533

(Loss) income from operations
Healthcare services	$	(80,327	)	$	(151,691	)
Product manufacturing and development		108,702			(554,842	)
Corporate		(3,346,012	)		(1,535,427	)
Income (loss) from operations	$	(3,317,637	)	$	(2,241,960	)

Depreciation and amortization
Healthcare services	$	30,035		$	28,968
Product manufacturing and development		262,927			309,042
Corporate		279,442			248,156
Depreciation and amortization	$	572,404		$	586,166

Capital expenditures
Healthcare services	$	-		$	-
Product manufacturing and development		-			-
Corporate		-			-
Capital expenditures	$	-		$	-

Interest expenses
Healthcare services	$	20,532		$	36,303
Product manufacturing and development		462			2,464
Corporate		122,380			128,476
Interest expenses	$	143,374		$	167,243

Net (loss) income
Healthcare services	$	(98,640	)	$	(185,713	)
Product manufacturing and development		48,883			(578,576	)
Corporate		(4,610,966	)		(3,172,447	)
Net loss	$	(4,660,723	)	$	(3,936,736	)

	As of November 30, 2023		As of August 31, 2023

Total assets
Healthcare services	$	5,002,855	$	5,158,851
Product Sales		18,748,475		17,993,652
Corporate		13,493,054		12,410,544
	$	37,244,384	$	35,563,047

Accounts receivable
Healthcare services	$	672,841	$	697,440
Product Sales		1,868,387		765,388
Corporate		94,946		4,200
	$	2,636,174	$	1,467,028

Intangible assets
Healthcare services	$	111,172	$	120,163
Product Sales		3,592,425		3,818,313
Corporate		12,000,621		12,280,063
	$	15,704,218	$	16,218,539

Goodwill
Healthcare services	$	518,918	$	520,821
Product Sales		7,035,861		7,061,662
Corporate		-		-
	$	7,554,779	$	7,582,483

Schedule of Foreign Currency Translation, Exchange Rate Used (Details)	Nov. 30, 2023	Aug. 31, 2023	Nov. 30, 2022
Period End [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7363	0.7390	0.7403
Average Period [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Foreign currency exchange rate	0.7324	0.7426	0.7414

Organization and Basis of Presentation (Details Narrative) - USD ($)					3 Months Ended
	Nov. 07, 2023	Nov. 06, 2023	May 09, 2017	Apr. 25, 2017	Nov. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	1-for-10 reverse stock split	1-for-10 reverse stock split			1-for-10 reverse stock split
Parent Company [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued in connection with reverse merger transaction			$ 6,904
Share Exchange Agreement [Member] \| NHL [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of restricted shares of common stock, shares				1,677,974
Percentage of common stock issued and outstanding				85.00%

Schedule of Estimated Useful lives of Assets (Details)	Nov. 30, 2023
Building [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	30 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	3 years
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, estimated lives	5 years

Schedule of Intangible Assets Amortized Estimated Useful Lives (Details)	Nov. 30, 2023
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	50 years
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	5 years
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated lives	7 years

Schedule of Changes in Goodwill (Details) - USD ($)	3 Months Ended	12 Months Ended
Schedule of Changes in Goodwill (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Beginning balance	$ 7,582,483	$ 7,825,844
Foreign currency translation adjustment	(27,704)	(243,361)
Ending balance	7,554,779	7,582,483
APKA Health, Inc. [Member]
Beginning balance	184,750	190,678
Foreign currency translation adjustment	(675)	(5,928)
Ending balance	184,075	184,750
Executive Fitness Leaders [Member]
Beginning balance	121,196	125,088
Foreign currency translation adjustment	(443)	(3,892)
Ending balance	120,753	121,196
Rockland [Member]
Beginning balance	214,310	221,188
Foreign currency translation adjustment	(783)	(6,878)
Ending balance	213,527	214,310
Acenzia Inc [Member]
Beginning balance	7,061,662	7,288,307
Foreign currency translation adjustment	(25,801)	(226,645)
Ending balance	7,035,861	7,061,662
12858461 Canada Corp [Member]
Beginning balance	565	583
Foreign currency translation adjustment	(2)	(18)
Ending balance	$ 563	$ 565

Summary of Significant Accounting Policies (Details Narrative)		3 Months Ended		12 Months Ended
	Nov. 07, 2023 shares	Nov. 30, 2023 USD ($) Integer shares	Nov. 30, 2022 USD ($) shares	Aug. 31, 2023 USD ($)
Allowance for uncollectible accounts receivable		$ 855,116		$ 864,215
Inventory
Other receivable written off
Impairment of long-lived assets		0
Impairment of intangible assets		$ 0
Contract lease term		12 months
Goodwill impairment charge
Debt conversion, converted instrument, shares issued \| shares	27,973
Foreign currency translation gain (loss)		$ 108,976	$ (420,982)	$ 922,609
Number of reportable segments \| Integer		2
Common Stock [Member]
Debt conversion, converted instrument, shares issued \| shares		3,786,454
Common Stock To Be Issued [Member]
Debt conversion, converted instrument, shares issued \| shares		17,375
Options/Warrants Outstanding [Member]
Potentially dilutive common stock options and warrants outstanding, shares \| shares		659,616	1,860,950
Terragenx Inc [Member]
Equity method investment, ownership percentage		91.00%
12858461 Canada Corp [Member]
Equity method investment, ownership percentage		50.10%
Novo Healthnet Kemptville Centre Inc [Member]
Equity method investment, ownership percentage		80.00%
Novo Earth Therapeutics Inc [Member]
Equity method investment, ownership percentage		70.00%

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Nov. 30, 2023	Aug. 31, 2023
6% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	6.00%	6.00%
13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Bearing interest rate	13.75%	13.75%
Related Party [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 458,266	$ 533,001
Related Party [Member] \| Non-Interest Bearing [Member]
Related Party Transaction [Line Items]
Due to related parties	376,701	451,137
Related Party [Member] \| 6% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties		21,267
Related Party [Member] \| 13.75% Interest Rate [Member]
Related Party Transaction [Line Items]
Due to related parties	$ 81,565	$ 60,597

Schedule of Accounts Receivable, Net (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Receivables [Abstract]
Trade receivables	$ 3,412,783	$ 2,223,243
Amounts earned but not billed	78,507	108,000
Accounts receivables gross	3,491,290	2,331,243
Allowance for doubtful accounts	(855,116)	(864,215)
Accounts receivable, net	$ 2,636,174	$ 1,467,028

Schedule of Inventory (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 516,811	$ 388,391
Work in process	108,244	81,696
Finished Goods	645,780	636,896
Inventory Gross	1,270,835	1,106,983
Allowance for slow moving and obsolete inventory
Inventory, net	$ 1,270,835	$ 1,106,983

Schedule of Other Receivables (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 1,047,742	$ 1,051,584
Current portion	(1,047,742)	(1,051,584)
Long-term portion
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	73,630	73,900
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	532,433	534,386
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Total other receivables	$ 441,679	$ 443,298

Schedule of Other Receivables (Details) (Parenthetical)	3 Months Ended	12 Months Ended
Schedule of Other Receivables (Details) (Parenthetical)	Nov. 30, 2023	Aug. 31, 2023
Advance to Corporation One [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12.00%	12.00%
Notes receivable due date	Jan. 31, 2024	Jan. 31, 2024
Advance to Corporation Two [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	12.00%	12.00%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024
Advance to Corporation Three [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of interest accrued per annum	10.00%	10.00%
Notes receivable due date	Feb. 01, 2024	Feb. 01, 2024

Schedule of Property and Equipment (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 6,619,035	$ 6,643,247
Accumulated depreciation	(1,312,422)	(1,253,209)
Total	5,306,613	5,390,038
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	441,780	443,400
Building [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	3,313,350	3,325,500
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	838,297	841,371
Clinical Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	1,909,678	1,916,681
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	33,381	33,504
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	44,400	44,502
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment gross	$ 38,149	$ 38,289

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 72,604	$ 60,043

Schedule of Intangible Assets (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 23,269,852	$ 23,290,546
Accumulated amortization	(7,565,634)	(7,072,007)
Total	15,704,218	16,218,539
Land Use Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	11,573,321	11,573,321
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	7,487,410	7,497,746
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	2,287,746	2,291,058
Brand Names [Member]
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets, gross	$ 1,921,375	$ 1,928,421

Schedule of Expected Amortization Expense of intangible Assets (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 2,003,586
2025	1,820,324
2026	1,454,624
2027	1,208,004
2028	639,025
Thereafter	8,578,655
Total	$ 15,704,218	$ 16,218,539

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
Intangible Assets (Details Narrative) - USD ($)	Nov. 30, 2023	Nov. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization of intangible assets	$ 499,800	$ 526,123

Schedule of Accrued Expenses (Details) - USD ($)	Nov. 30, 2023	Aug. 31, 2023
Payables and Accruals [Abstract]
Accrued liabilities	$ 1,049,543	$ 961,897
Accrued payroll	215,936	236,218
Unearned revenue	35,070	35,434
Accrued expense	$ 1,300,549	$ 1,233,549

Schedule of Governmental Loans and Note Payable (Details) - USD ($)

3 Months Ended

12 Months Ended

Nov. 30, 2023

Aug. 31, 2023

Notes Payable One [Member]

$ 157,265

$ 342,443

Less current portion

(93,488)

(277,405)

Long-term portion

63,777

65,038

Notes Payable Two [Member]

^[1]

88,356

88,680

Notes Payable Three [Member]

40,320

Debt instrument, maturity date

$ 28,589

$ 28,693

Dec. 02, 2028

Notes Payable Four [Member]

Notes Payable Five [Member]

$ 73,900